QIAGEN Expands Digital PCR Portfolio to Boost Biopharma Adoption
Event summary
- QIAGEN is expanding its QIAcuity digital PCR (dPCR) ecosystem with new gene expression solutions, workflow automation, and enhanced analysis capabilities.
- New QIAcuity Gene Expression Assays and the QIAcuity OneStep High Multiplex Probe PCR Kit will support gene expression analysis across human, mouse, and rat research applications.
- QIAcuity Software 3.5, scheduled for release later this month, introduces advanced analysis templates and automated reporting capabilities.
- QIAGEN has over 3,200 cumulative QIAcuity placements worldwide, with more than 400 customers operating multiple instruments.
The big picture
QIAGEN's expansion of its QIAcuity digital PCR portfolio aligns with the growing demand for higher sensitivity, precision, and multiplexing capabilities in molecular biology. The company is positioning itself as a key player in the transition from traditional qPCR technologies to more advanced dPCR solutions, particularly in the biopharma sector. With over 3,200 cumulative placements and a strong customer base, QIAGEN is well-positioned to capitalize on the increasing adoption of digital PCR technologies.
What we're watching
- Market Adoption
- How QIAGEN's expanded QIAcuity ecosystem will accelerate the transition from qPCR to dPCR across research and biopharma applications.
- Technological Integration
- Whether the collaboration with Hamilton for laboratory automation will enhance productivity and reduce manual handling risks.
- Competitive Positioning
- The pace at which QIAGEN can differentiate its dPCR solutions in a competitive biopharma market.
Related topics